Рет қаралды 38,792
Obesity is the leading preventable cause of death, with about a third of North Americans classified as obese. One of the few effective treatments was bariatric surgery. Health Canada recently approved a new weight loss drug, semaglutide, also known by the brand names “Ozempic” or “Wegovy.” Experts refer to it as a “game changer” for its ability to curtail appetite and spur weight loss.
In this episode, Medcan’s director of weight management, Dr. David Macklin, a co-author of Canada’s national guidelines for obesity treatment, provides host Shaun Francis with a Ozempic (semaglutide) explainer. “We’re in a super exciting stage in my field of medicine,” Dr. Macklin says. “I can safely say that 2022, for a number of reasons, will be characterized in history as the first time that we have a very effective non-surgical treatment for [obesity].”
For complete episode links and time-coded insights, visit the Eat Move Think episode 115 web page at the following: eatmovethinkpodcast.com/podcast/ep115-is-semaglutide-right-for-me